Canada and the Orphan Drug Framework--Where Are We Now?

Posted 11 December 2014 By Patricia Anderson, RAC

placeholder+image Canada is in the final stages of developing an orphan drug policy for drugs affecting populations of 5 in 10,000 people. Bill C-17 has passed the legislature and is awaiting final approval. The new policy will then be open for comment. Fee mitigation, accelerated review and HTA collaboration are incentives but marketing exclusivity is not, although discussions on that topic are taking place. The final hurdle is provincial and private payment plans.

Share this article:

Categories: Prescription drugs, Orphan products, Government affairs, Reimbursement, Features, Canada, FDA, EMA, Health Canada

Tags: orphan drugs, Bill C-17, Vanessa's law, payment plans

Regulatory Exchange: Latest Updates From the Community